Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
| ▸ | NOS3 | P29474 | 2/20 | 0.43 |
| ▸ | NOS1 | P29475 | 2/20 | 0.43 |
| ▸ | NOS2 | P35228 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21449754 | 0.97 | SLC18A3 (0.55) | SLC18A3HDAC1HDAC8HDAC6BACE1 | |
| SCHEMBL22291709 | 0.97 | SLC18A3 (0.55) | SLC18A3HDAC1HDAC8HDAC6BACE1 | |
| SCHEMBL7301118 | 0.97 | SLC18A3 (0.55) | SLC18A3HDAC1HDAC8HDAC6BACE1 | |
| SCHEMBL23192020 | 0.97 | SLC18A3 (0.55) | SLC18A3HDAC1HDAC8HDAC6BACE1 | |
| SCHEMBL112829 | 0.97 | SLC18A3 (0.55) | SLC18A3HDAC1HDAC8HDAC6BACE1 | |
| SCHEMBL24096570 | 0.97 | SLC18A3 (0.55) | SLC18A3HDAC1HDAC8HDAC6BACE1 | |
| Hydrochloric Acid SCHEMBL4986182 | 0.95 | SLC18A3 (0.53) | SLC18A3HDAC1HDAC8HDAC6BACE1 | |
| SCHEMBL3484987 | 0.95 | SLC18A3 (0.52) | SLC18A3HDAC1HDAC8HDAC6BACE1 | |
| SCHEMBL8579595 | 0.91 | SLC18A3 (0.50) | SLC18A3HDAC1HDAC8HDAC6BACE1 | |
| SCHEMBL1128088 | 0.89 | SLC18A3 (0.50) | SLC18A3KMT2AMAPTMEN1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4676926-A1 | BICYCLIC HETEROARYL COMPOUNDS FOR USE AS GPR35 MODULATORS | ThirtyFiveBio Limited (GB) | 2026-01-14 | — | — | EP | disclosed |
| CN-116023321-B | STING inhibitor prodrug and medical application thereof | 中国药科大学 | 2024-11-29 | — | — | CN | disclosed |
| WO-2024184650-A1 | BICYCLIC HETEROARYL COMPOUNDS FOR USE AS GPR35 MODULATORS. | ThirtyFiveBio Limited (GB) | 2024-09-12 | — | — | WO | disclosed |
| WO-2024028169-A1 | NOVEL SPECIFICALLY SUBSTITUTED THIOPHENOLIC COMPOUNDS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2024-02-08 | — | — | WO | disclosed |
| EP-3792270-B1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE | SAMSUNG ELECTRONICS CO LTD (KR) | 2023-12-13 | — | — | EP | disclosed |
| CN-117148673-A | Photosensitive composition and method for producing same, cured product and method for producing same, display element, and polyimide | JSR株式会社 | 2023-12-01 | — | — | CN | disclosed |
| EP-3858945-B1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORP (US) | 2023-11-29 | — | — | EP | disclosed |
| EP-3912983-B1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING ORGANOMETALLIC COMPOUND, AND ELECTRONIC APPARATUS INCLUDING ORGANIC LIGHT-EMITTING DEVICE | SAMSUNG ELECTRONICS CO LTD (KR) | 2023-11-15 | — | — | EP | disclosed |
| EP-4231806-A1 | ORGANIC LIGHT-EMITTING DEVICE AND ELECTRONIC APPARATUS INCLUDING THE SAME | Samsung Electronics Co., Ltd. (KR) | 2023-08-23 | — | — | EP | disclosed |
| US-20230192613-A1 | Charged Ion Channel Blockers and Methods for Use | NOCION THERAPEUTICS INC (US) | 2023-06-22 | — | — | US | disclosed |
| US-20080269293-A1 | PYRAZOLE DERIVATIVES AS ANTI-PLATELET AND ANTI-THROMBOTIC AGENTS | PFIZER INC. | 2008-10-30 | — | — | US | disclosed |
| US-20080269293-A1 | PYRAZOLE DERIVATIVES AS ANTI-PLATELET AND ANTI-THROMBOTIC AGENTS | PFIZER INC. | 2008-10-30 | — | — | US | disclosed |
| WO-2008117175-A2 | NOVEL BENZAMIDE DERIVATIVES AS MODULATORS OF THE FOLLICLE STIMULATING HORMONE | ADDEX PHARMA SA (CH) | 2008-10-02 | — | — | WO | disclosed |
| EP-1962855-A2 | TRPA1 INHIBITORS FOR TREATING PAIN | Hydra Biosciences, Inc. (US) | 2008-09-03 | — | — | EP | disclosed |
| WO-2008023235-A1 | PYRAZOLE DERIVATIVES AS ANTI-PLATELET AND ANTI-THROMBOTIC AGENTS | PFIZER PRODUCTS INC. (US) | 2008-02-28 | — | — | WO | disclosed |
| US-20070219222-A1 | Inhibit Transient Receptor Potential A1 (TRPA1) activity ; incontinence | HYDRA BIOSCIENCES (US) | 2007-09-20 | — | — | US | disclosed |
| WO-2007073505-A2 | TRPA1 INHIBITORS FOR TREATING PAIN | HYDRA BIOSCIENCES, INC. (US) | 2007-06-28 | — | — | WO | disclosed |
| US-20070060582-A1 | 1,4-Disubstituted isoquinilone derivatives as raf-kinase inhibitors useful for the treatment of proliferative diseases | FINK CYNTHIA A | 2007-03-15 | — | — | US | disclosed |
| EP-1753740-A2 | AMINO CYCLOPENTYL HETEROCYCLIC AND CARBOCYCLIC MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Merck & Co., Inc. (US) | 2007-02-21 | — | — | EP | disclosed |
| WO-2006001958-A2 | AMINO CYCLOPENTYL HETEROCYCLIC AND CARBOCYCLIC MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 2006-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269293-A1 | PYRAZOLE DERIVATIVES AS ANTI-PLATELET AND ANTI-THROMBOTIC AGENTS | P2RY1, P2RY11, P2RX7 | SLC18A3 4299/4885HDAC1 3668/4885HDAC8 3206/4885 |
| US-20070060582-A1 | 1,4-Disubstituted isoquinilone derivatives as raf-kinase inhibitors useful for the treatment of proliferative diseases | BRAF, RAF1, NRAS | SLC18A3 4108/4885HDAC1 1784/4885HDAC8 2522/4885 |
| US-20230192613-A1 | Charged Ion Channel Blockers and Methods for Use | TRPV1, TRPV2, TRPV5 | SLC18A3 343/4885HDAC1 1625/4885HDAC8 2397/4885 |
| US-20070219222-A1 | Inhibit Transient Receptor Potential A1 (TRPA1) activity ; incontinence | TRPA1, TRPV1, TRPV2 | SLC18A3 62/4885HDAC1 1013/4885HDAC8 894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.